Healthcare Distribution Alliance – Patients Move Us.
Share Print


The First 90 Days: U.S. Biopharma Finished Goods Supply Chain Response to COVID-19

September 16, 2020 | 11:30 AM (Eastern)

Developed in collaboration with Deloitte Consulting LLP, the US Biopharmaceutical Finished Goods Supply Chain Response to COVID-19 report provides insights into the role that the supply chain played in ensuring delivery and availability of medicines during the first 90 days of the COVID-19 pandemic. In this webinar, you will receive an in-depth look at key findings from the report, including:

  • Analysis of the key challenges presented by the pandemic;
  • Evaluation of the industry performance in response to the challenges surfaced during the pandemic;
  • Implications of scenarios that could unfold within the next 6-12 months; and
  • Recommendations for the industry to build resilience to future disruptions.

The report will be published and made available as a complimentary download through the HDA website later this Fall.


Rob Jacoby, Principal, Deloitte Consulting LLP

Matt Heim, Senior Manager, Deloitte Consulting LLP

Cinthya Fernandez Preda, Manager, Deloitte Consulting LLP

Perry Fri, Executive Vice President, Industry Relations, Membership & Education, HDA; COO, HDA Research Foundation (Moderator)

© 2020 Healthcare Distribution Alliance. All rights reserved.
HDA: E | C | C2 | NF | O365